CClinicalTrials.gg
TerminatedNCT03500744Updated Oct 5, 2023

Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery

An interventional study of Erector spinae plane block and Sham block in Hysterectomy, Cystectomy and Regional Anesthesia, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Treatment

Why this study was terminated
Inability to recruit due to COVID situation and protocols
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Regional anesthesia, also know as a nerve block, is a key component of pain control after major abdominal surgery. Bilateral erector spinae plane block (ESPB) performed at low thoracic level has been shown to be an effective pain control method in case reports. This pilot study aims to further characterize the pain-control characteristics and to provide baseline data for future trials.

02

Conditions studied

  • Hysterectomy
  • Cystectomy
  • Regional Anesthesia
03

In context

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 309 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Adult surgical patients who are American Society of Anesthesiologists (ASA) class I to III, undergoing cystectomy, or total abdominal hysterectomy, salpingo-oophrectomy with or without omentectomy via midline laparotomy.

Exclusion criteria

Exclusion Criteria:

  1. BMI > 40
  2. Non-English speaking
  3. Patient refusal or inability to consent
  4. Cognitive or psychiatric history that would make it difficult to assess pain score
  5. Pre-existing chronic pain condition
  6. Preoperative opioid use greater than the equivalent of oral morphine 30 mg daily
  7. Infection over site of block placement
  8. Allergy or contraindication to any study medication
  9. Coagulopathy or thrombocytopenia
  10. Postoperative ICU admission
  11. Presence of significant cardiac, respiratory, hepatic, renal or neurologic diseases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Erector spinae plane block

    The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side. Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids.

    Procedure: Erector spinae plane block

  • Sham comparator
    Shame block

    A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed. Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids.

    Procedure: Sham block

Interventions

  • ProcedureErector spinae plane block

    Ropivacaine 0.5% 20 mL at each site of ESPB

  • ProcedureSham block

    Skin infiltration only

06

What researchers measure

Primary outcomes

  1. Opioid consumption

    Postoperative opioid consumption in oral morphine equivalents

    Time frame: First 12 postoperative hour

  2. Pain score

    Numeric rating scale (0 - 10) for pain score, area under curve first 12 hours

    Time frame: First 12 postoperative hour

Secondary outcomes

  1. Length of stay in post-anesthetic recovery unit

    Length of stay in post-anesthetic recovery unit

    Time frame: until discharge from post-anesthetic recovery unit, up to 4 hours postoperaively

  2. Length of stay in hospital

    Length of stay in hospital

    Time frame: until discharge from hospital, up to 7 days postoperatively

  3. Number of participants with opioid related complication

    Nausea, vomiting, pruritus

    Time frame: Until discharge, up to 7 days postoperatively

  4. Number of participants with block related complication

    Hematoma, nerve deficit, pneumothorax

    Time frame: Until discharge, up to 7 days postoperatively

  5. Pain score 12 - 24 hour

    Area under curve of Numeric rating scale(0 - 10) pain score during the 12 to 24th postoperative hour

    Time frame: 12th to 24th postoperative hour

  6. Opioid consumption 12 - 24 hour

    Postoperative opioid consumption in oral morphine equivalents

    Time frame: 12th to 24th postoperative hour

07

Study locations

1 site
  • Cheng Lin
    London, Ontario n6c6a7, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03500744
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Responsible party
Kamal Kumar (Associate Professor, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Apr 18, 2018
Start date
Sep 1, 2019
Primary completion
Aug 1, 2022
Completion
Aug 1, 2022
Last update
Oct 5, 2023

Study contacts

Cheng Lin
principal investigator · Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion